Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
|
UK |
|
Uni-charm Indonesia PT
IDX:UCID
|
ID |
|
Resource Development Group Ltd
ASX:RDG
|
AU |
|
A
|
Alimak Group AB (publ)
LSE:0R8W
|
SE |
|
Redline Communications Group Inc
TSX:RDL
|
CA |
|
M
|
Mitsubishi Logistics Corp
F:MIB
|
JP |
|
M
|
Motic Xiamen Electric Group Co Ltd
SZSE:300341
|
CN |
|
Haynes International Inc
NASDAQ:HAYN
|
US |
|
Ashima Ltd
NSE:ASHIMASYN
|
IN |
|
H
|
Hitit Bilgisayar Hizmetleri AS
IST:HTTBT.E
|
TR |
|
Playtech PLC
LSE:PTEC
|
IM |
|
F
|
Fuerte Metals Corp
XTSX:FMT
|
CA |
|
Z
|
Zhejiang Construction Investment Group Co Ltd
SZSE:002761
|
CN |
|
Shreyans Industries Ltd
NSE:SHREYANIND
|
IN |
|
H
|
Hainan Shennong Technology Co Ltd
SZSE:300189
|
CN |
Barinthus Biotherapeutics PLC
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The company is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. The company is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The company is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. The company is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
